Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN) and BELLUS Health (NASDAQ: BLU)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Amgen (AMGNResearch Report) and BELLUS Health (BLUResearch Report) with bullish sentiments.

Amgen (AMGN)

Cowen & Co. analyst Yaron Werber maintained a Buy rating on Amgen yesterday and set a price target of $253.00. The company’s shares closed last Monday at $220.86, close to its 52-week high of $225.26.

According to TipRanks.com, Werber is a 5-star analyst with an average return of 10.4% and a 59.3% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Springworks Therapeutics, and Rocket Pharmaceuticals.

Amgen has an analyst consensus of Moderate Buy, with a price target consensus of $229.00, which is a 4.3% upside from current levels. In a report issued on November 12, SunTrust Robinson also initiated coverage with a Buy rating on the stock with a $256.00 price target.

See today’s analyst top recommended stocks >>

BELLUS Health (BLU)

In a report released yesterday, Ritu Baral from Cowen & Co. maintained a Buy rating on BELLUS Health. The company’s shares closed last Monday at $6.55.

According to TipRanks.com, Baral is a 5-star analyst with an average return of 17.3% and a 45.9% success rate. Baral covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Milestone Pharmaceuticals, and Madrigal Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for BELLUS Health with a $14.92 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.